0000950123-25-000372.txt : 20250117 0000950123-25-000372.hdr.sgml : 20250117 20250117163021 ACCESSION NUMBER: 0000950123-25-000372 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20250117 DATE AS OF CHANGE: 20250117 EFFECTIVENESS DATE: 20250117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: KAZIA THERAPEUTICS LTD CENTRAL INDEX KEY: 0001075880 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: C3 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-535685 FILM NUMBER: 25539083 BUSINESS ADDRESS: STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24, STREET 2: 300 BARANGAROO AVENUE CITY: SYDNEY NSW STATE: C3 ZIP: 2000 BUSINESS PHONE: 01161298780088 MAIL ADDRESS: STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24, STREET 2: 300 BARANGAROO AVENUE CITY: SYDNEY NSW STATE: C3 ZIP: 2000 FORMER COMPANY: FORMER CONFORMED NAME: NOVOGEN LTD DATE OF NAME CHANGE: 19981228 D 1 primary_doc.xml X0708 D LIVE 0001075880 KAZIA THERAPEUTICS LTD Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 (+)61-2-9472-4101 AUSTRALIA Novogen Ltd NOVOGEN LTD Corporation true John Friend Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Director Bryce Carmine Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Steven Coffey Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Ebru Davidson Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Robert Apple Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Director Jeffrey Bonacorda Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Elissa Hansen Level 24, Three International Towers 300 Barangaroo Avenue Sydney C3 AUSTRALIA 2000 Executive Officer Biotechnology Decline to Disclose 06b false 2025-01-10 false true true false 0 Maxim Group LLC 120708 None None 300 Park Avenue New York NY NEW YORK 10022 FL FLORIDA 2060000 2060000 0 The Issuer issued a warrant to purchase 1,333,333 ADS, each representing 100 Issuer's ordinary shares, to the investor, and a warrant to purchase 40,000 ADSs to the placement agent. Total amount is calculated using warrant exercise price of $1.5 per ADS. false 1 0 true 0 In connection with the registered direct offering (RDO) concurrent with this private placement, the placement agent received a fee of up to 7% of the gross proceeds of the RDO and the warrant to purchase 40,000 ADSs exercisable at $1.5 per ADS 0 false Kazia Therapeutics Ltd /s/ John Friend John Friend Chief Executive Officer 2025-01-17